← Eichor
Study identifier: NCT07222462 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

A Superiority Trial of Radiofrequency Ablation for Low Back Pain

Condition: Chronic Low Back Pain (CLBP)  ·  Sponsor: University of Washington

PhaseNA
Planned participants300
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

The purpose of the ASTRAL Study is to evaluate the effectiveness of LRFA (Lumbar radiofrequency ablation) against a control procedure. The ASTRAL Study will enroll individuals with chronic low back pain (CLBP) and randomly assign them to one of three groups: lumbar radiofrequency ablation using conventional electrodes placed parallel to the medial branch nerves (LRFA-C), lumbar radiofrequency ablation using multi-tined electrodes placed perpendicular to the medial branch nerves (LRFA-M), or a simulated radiofrequency ablation procedure.

This description comes directly from the study's public registry record.

Talk to the study team

Research Study Coordinator  ·  206-210-4040  ·  astralstudy@uw.edu

Always discuss trial participation with your own doctor first.

Locations (3)

Emory Musculoskeletal InstituteAtlanta, Georgia, United StatesRecruiting
Cleveland ClinicCleveland, Ohio, United StatesRecruiting
University of Utah Orthopaedic Center/PM&RSalt Lake City, Utah, United StatesNot Yet Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07222462